为贯彻落实《中华人民共和国公司法》（以下简称"《公司法》"）、《上市 公司章程指引》等相关法律、行政法规、部门规章和规范性文件，进一步完善公司 治理结构，提升公司规范运作水平，结合公司的实际情况，公司将不再设置监事会， 由公司董事会审计委员会行使《公司法》规定的监事会的职权，公司《监事会议事 规则》相应废止，公司各项治理制度中涉及监事会、监事的规定不再适用。 证券代码：688389 证券简称：普门科技 公告编号：2025-080 深圳普门科技股份有限公司 关于取消监事会、修订《公司章程》及相关议事规则 暨制定、修订部分公司治理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳普门科技股份有限公司（以下简称"公司"）于2025年11月26日召开了第 三届董事会第二十次会议，审议通过了《关于取消监事会、修订〈公司章程〉及相 关议事规则的议案》《关于制定、修订部分公司治理制度的议案》。同日，公司召 开了第三届监事会第十九次会议，审议通过了《关于取消监事会、修订〈公司章程〉 及相关议事规则的议案》《关于修订部分公司治 ...

证券代码：688389 证券简称：普门科技 公告编号：2025-083 深圳普门科技股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 （五） 网络投票的系统、起止日期和投票时间 股东大会召开日期：2025年12月16日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 2025年第一次临时股东大会 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 12 月 16 日 14 点 00 分 召开地点：广东省深圳市龙华区求知东路 8 号普门科技总部大厦 22 楼会议 室 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 12 月 16 日 至2025 年 1 ...

一、监事会会议召开情况 深圳普门科技股份有限公司（以下简称"公司"）于2025年11月26日以现场 会议方式召开了第三届监事会第十九次会议。会议通知已于2025年11月21日以电 话、邮件等方式送达全体监事。本次会议由监事会主席刘敏女士召集并主持，会 议应出席监事3人，实际出席监事3人，董事会秘书路曼女士列席本次会议。会议 的召集和召开程序符合《中华人民共和国公司法》和《公司章程》等相关规定。 二、监事会会议审议情况 证券代码：688389 证券简称：普门科技 公告编号：2025-082 深圳普门科技股份有限公司 第三届监事会第十九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 表决结果：同意3票、反对0票、弃权0票。 经全体监事表决，形成决议如下： （一）审议通过《关于取消监事会、修订〈公司章程〉及相关议事规则的 议案》 经审议，全体监事一致认为，公司取消监事会事项符合《中华人民共和国公 司法》《上市公司章程指引》等相关法律法规的规定，同意不再设置监事会，由 公司董事会审计委员会行使《中华人民共和国公司法 ...

证券代码：688389 证券简称：普门科技 公告编号：2025-081 深圳普门科技股份有限公司 第三届董事会第二十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 深圳普门科技股份有限公司（以下简称"公司"）于 2025 年 11 月 26 日以 现场会议与通讯相结合方式召开了第三届董事会第二十次会议。本次会议通知 已于 2025 年 11 月 21 日以电话、邮件等形式送达公司全体董事。本次会议由董 事长刘先成先生召集并主持，会议应参加董事 9 人，实际参加董事 9 人。公司 监事、高级管理人员列席本次会议。本次会议的召集、召开程序符合有关法律 法规和《公司章程》的相关规定。 二、董事会会议审议情况 经全体董事表决，形成决议如下： （一）审议通过《关于取消监事会、修订〈公司章程〉及相关议事规则的 议案》 为贯彻落实《中华人民共和国公司法》《上市公司章程指引》等相关法律、 行政法规、部门规章和规范性文件，进一步完善公司治理结构，提升公司规范 运作水平，结合公司的实际情况，全体董事一致 ...

Core Viewpoint - The increasing prevalence of chronic respiratory diseases in China, particularly among individuals over 40, is driving the demand for sputum suction machines, with a notable rise in procurement following the COVID-19 pandemic [1][8]. Market Overview - The total procurement of sputum suction machines in China reached 4,109 units in 2023, marking a year-on-year increase of 65.49%, with a total procurement value of 118 million yuan, up 43.90% [1][8]. - In 2024, the procurement volume is expected to decline to 3,154 units, with a total value of 89 million yuan and an average price of 28,200 yuan per unit [1][8]. Industry Development - Sputum suction machines have evolved from manual devices in the early 20th century to electric models in the 1950s, and further advancements have led to the introduction of ultrasonic technology and smart devices in the 21st century [3][4]. - The market for sputum suction machines is supported by government policies aimed at enhancing the medical device industry, which is considered a strategic emerging industry in China [5][6]. Industry Chain - The upstream of the sputum suction machine industry includes medical-grade plastics, rubber, motors, control systems, and sensors, while the midstream consists of manufacturing companies, and the downstream includes hospitals and rehabilitation centers [6][7]. - The demand for sputum suction machines is primarily driven by hospitals, especially top-tier hospitals where the configuration rate exceeds 90% [6]. Competitive Landscape - Domestic sputum suction machines have gained a significant market share, reaching 76.67% in 2024, while imported brands still hold a substantial position in the high-end market [8]. - The CR5 model of sputum suction machines holds a market share of 47.93%, with the leading brands being Heima, Pumen, and Siya [8]. Future Trends - Future developments in sputum suction machines are expected to include more sensors and smart algorithms for automatic parameter adjustments based on patient needs, as well as broader applications of IoT technology for remote monitoring and data transmission [12].

Group 1 - EVE Energy signed a procurement framework agreement with its affiliate, Smoore International, for continuous procurement of battery cells starting from January 1, 2026 [1] - Zhaoyi Information plans to issue H-shares and list on the Hong Kong Stock Exchange [1] - Fuke Environmental announced a change in its stock abbreviation to "Fuke Technology" effective November 26 [1] Group 2 - Dajia Weikang's shareholder and director terminated a share reduction plan ahead of schedule, having reduced 1% of total shares [2] - Aohong Electronics received approval from the China Securities Regulatory Commission for the issuance of convertible bonds [2] - Yingfeng Environment's controlling shareholder plans to issue exchangeable bonds not exceeding 1 billion yuan [2] Group 3 - Longshen Rongfa's subsidiary obtained a renewed drug production license covering various pharmaceutical products [4] - Xinhua News' subsidiary invested 15 million yuan in a fund with a total commitment of 221 million yuan [5] - Guang'an Aizhong appointed two new deputy general managers [6] Group 4 - Fosun Pharma's subsidiary's drug for gastric cancer treatment was included in the breakthrough therapy program by the National Medical Products Administration [7] - Nanjiao Foods reported a significant decline in October net profit due to rising raw material costs [8] - Nanfeng Co. won two nuclear power project bids totaling 928.7 million yuan [10] Group 5 - Puluo Pharmaceutical received a drug registration certificate for its Cefdinir capsules [11] - Liming Co.'s subsidiary received environmental approval for a new pesticide raw material project [12] - Longhua New Materials' expansion project for polyether polyols has commenced trial production [13] Group 6 - Pumen Technology's products received IVDR CE certification from TÜV Rheinland [15] - China Chemical reported new contracts worth 312.67 billion yuan from January to October [18] - China Nuclear Construction achieved new contracts totaling 123.84 billion yuan as of October [19] Group 7 - Changshu Bank's executives plan to purchase at least 550,000 shares of the bank [20] - Shandong Steel's subsidiary is applying for bankruptcy liquidation to focus on core business [21] - Huakang Clean is expected to win a bid for a purification system project worth 176 million yuan [23] Group 8 - Huawu Co. plans to internally transfer subsidiary equity [24] - Tianen Kang's subsidiary received clinical trial acceptance for a new drug [26] - Tianyi Medical's subsidiary obtained a medical device registration certificate for a blood dialysis product [27] Group 9 - Xuelang Environment is facing a pre-restructuring application from creditors [27] - Chitianhua's subsidiary resumed production after passing safety inspections [28] - Huaping Co.'s director plans to reduce 0.03% of company shares [30] Group 10 - Xizhuang Co. plans to establish a wholly-owned subsidiary in Singapore [31] - Ruisheng Intelligent's subsidiary won a 60.23 million yuan ICT project bid [32] - Junyi Digital plans to invest 120 million yuan in Guanghong Precision [33] Group 11 - Fuguang Co.'s controlling shareholder plans to increase holdings between 80 million to 150 million yuan [34] - Ganyue Express reported a 13.68% increase in logistics revenue in October [39] - Jiangsu Sop terminated its 2025 private placement plan [41] Group 12 - Langke Intelligent's shareholders plan to reduce a total of 1.68% of company shares [42] - Yuantong Express reported an 8.97% increase in express product revenue in October [45] - Jinbei Automotive plans to invest 158 million yuan to acquire 52% of Zhongtuo Technology [46]

本次获得 MDSAP 认证的产品满足巴西、美国监管机构对相关医疗器械质 量管理体系的要求，可以在巴西、美国替代部分审核和常规检查，有助于降低 公司相关产品的审核成本、提升管理效率，对公司未来的海外市场拓展将产生 积极影响。 三、风险提示 证券代码：688389 证券简称：普门科技 公告编号：2025-079 深圳普门科技股份有限公司 关于自愿披露获得MDSAP认证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，深圳普门科技股份有限公司（以下简称"公司"）获得由 TÜV SÜD America Inc.颁发的"医疗器械单一审核程序"（Medical Device Single Audit Program，MDSAP）认证证书。具体情况如下： 二、对公司的影响 MDSAP 是国际医疗器械监管机构论坛（IMDRF）成员共同发起的项目， 旨在医疗器械制造商通过 MDSAP 认可的审核组织的一次审核，即可满足不同 国家的质量管理体系要求。 2 / 2 1 / 2 一、MDSAP 认证证书的具体情况 证书编号 QS6 0 ...

Core Viewpoint - Pumen Technology (688389.SH) has received IVDRCE certification from TüV Süd, enabling its 26 electrochemical luminescent reagent products and hemoglobin chromatography columns to enter the EU market, enhancing its competitiveness in the in vitro diagnostic sector [1] Group 1 - The IVDRCE certification is a requirement for entering the EU market under the EU In Vitro Diagnostic Medical Devices Regulation [1] - The certification is expected to positively impact the company's future operations and market presence [1] - The products certified will also be recognized in other regions that accept IVDRCE certification, broadening the company's market opportunities [1]

格隆汇11月20日丨普门科技(688389.SH)公布，公司获得由TüVSüDAmericaInc.颁发的"医疗器械单一审 核程序"（MedicalDeviceSingleAuditProgram，MDSAP）认证证书。MDSAP是国际医疗器械监管机构论 坛（IMDRF）成员共同发起的项目，旨在医疗器械制造商通过MDSAP认可的审核组织的一次审核，即 可满足不同国家的质量管理体系要求。本次获得MDSAP认证的产品满足巴西、美国监管机构对相关医 疗器械质量管理体系的要求，可以在巴西、美国替代部分审核和常规检查，有助于降低公司相关产品的 审核成本、提升管理效率，对公司未来的海外市场拓展将产生积极影响。 ...

Core Points - The company, Pumen Technology (688389.SH), announced that 26 of its electrochemical luminescence reagent products and hemoglobin chromatography columns have received IVDR CE certification from TÜV SÜD, a European Union notified body [1] - The new EU In Vitro Diagnostic Medical Devices Regulation (IVDR, EU2017/746) replaces the previous In Vitro Diagnostic Medical Devices Directive (IVDD, 98/79/EC) for managing in vitro diagnostic medical devices in the EU market [1] - To date, the company has a total of 53 electrochemical luminescence reagent products that have obtained IVDR CE certification [1]